Valuation Actinium Pharmaceuticals, Inc. Deutsche Boerse AG
Stocks
7AY1
US00507W2061
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7080 EUR | -0.56% |
|
-7.21% | -39.80% |
Company Valuation: Actinium Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 132.4 | 271.4 | 139.3 | 39.31 | 42.43 | 25.46 | - | - |
| Change | - | 104.97% | -48.69% | -71.77% | 7.94% | -39.99% | - | - |
| Enterprise Value (EV) | 132.4 | 271.4 | 62.58 | 39.31 | 42.43 | 25.46 | 25.46 | 25.46 |
| Change | - | 104.97% | -76.94% | -37.19% | 7.94% | -39.99% | 0% | 0% |
| P/E | -5.01x | -7.77x | -2.78x | -0.99x | -1.25x | -0.96x | -1.45x | -3.29x |
| PBR | 1.81x | - | 3.72x | - | - | - | - | - |
| PEG | - | -0.5x | -0.1x | 0x | 0.1x | 0x | 0x | 0.1x |
| Capitalization / Revenue | 116x | 263x | 1,719x | - | 471x | - | 1.97x | 0.74x |
| EV / Revenue | 0x | 0x | 0x | - | 0x | - | 1.97x | 0.74x |
| EV / EBITDA | -0x | -0x | -0x | -0x | -0x | -0.83x | -0.73x | -0.66x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -0.83x | -1x | -1.68x |
| EV / FCF | -0x | 0x | -0x | -0x | - | -1.63x | -10.6x | 1.97x |
| FCF Yield | -15.9% | 3.05% | -34.1% | -84.2% | - | -61.4% | -9.43% | 50.7% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.2 | -1.37 | -1.83 | -1.27 | -1.09 | -0.8467 | -0.56 | -0.2467 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 1.144 | 1.03 | 0.081 | - | 0.09 | - | 12.93 | 34.58 |
| EBITDA 1 | -24.44 | -33.4 | -51.13 | -41.31 | -35.43 | -30.5 | -34.8 | -38.3 |
| EBIT 1 | -24.96 | -34.1 | -51.92 | -42.12 | -36.25 | -30.5 | -25.48 | -15.17 |
| Net income 1 | -24.77 | -33.02 | -48.82 | -38.24 | -33.89 | -28.5 | -23.27 | -12.34 |
| Net Debt | - | - | -76.68 | - | - | - | - | - |
| Reference price 2 | 6.0100 | 10.6500 | 5.0800 | 1.2600 | 1.3600 | 0.8115 | 0.8115 | 0.8115 |
| Nbr of stocks (in thousands) | 22,031 | 25,483 | 27,413 | 31,196 | 31,196 | 31,375 | - | - |
| Announcement Date | 3/25/22 | 3/31/23 | 3/29/24 | 3/31/25 | 3/30/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 21.25x | 6.51x | 14.24x | 1.5% | 56.54B | |
| 31.6x | 7.8x | 24.02x | 0.05% | 53.6B | |
| -17.91x | 4.18x | -7.32x | -.--% | 22.91B | |
| -38.06x | 12.21x | -36.05x | -.--% | 21.37B | |
| 25.45x | 4.98x | 13.18x | -.--% | 20.27B | |
| 24.28x | 4.73x | 15.36x | -.--% | 17.56B | |
| -737.38x | 35.03x | -3943.97x | -.--% | 14.75B | |
| 40.7x | 16.37x | 42.16x | 0.09% | 13.53B | |
| 16.73x | 4.82x | 11.24x | -.--% | 13.33B | |
| Average | -70.37x | 10.74x | -429.68x | 0.18% | 25.98B | |
| Weighted average by Cap. | -32.01x | 9.11x | -238.39x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ATNM Stock
- 7AY1 Stock
- Valuation Actinium Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
